ACR* Recommendations include MBDA† (Vectra®) as a disease activity measure that meets minimum standards for regular use for patients with rheumatoid arthritis



46 disease activity measures were assessed¹




Only 11 measures met a minimum standard for regular use¹



Vectra is among the 11 disease activity measures that can be used at an RA patient's regular clinical assessment visits¹



Vectra can help assist clinicians with adhering to a treat-to-target approach for the **management of RA**¹



*© American College of Rheumatology. All Rights Reserved onlinelibrary.wiley.com/doi/full/10.1002/acr.24042

Copyright © 2000-2019 by John Wiley & Sons, Inc. or related companies. All rights reserved

[†]Multi-Biomarker Disease Activity Score

Integrate Vectra® into Rheumatoid Arthritis Patient Care



MANAGEMENT DECISIONS

Patient and provider agree to make a treatment change



Test at baseline and at time of treatment change decision



Therapy Initiation or Change:

Until the desired treatment target is reached drug therapy should be adjusted every 3-6 months



THERAPY MONITORING

Evaluate if treatment is working



Test at 3-6 months after treatment change



Primary Goal:

Achieving a state of disease remission in RA is considered a primary treatment goal



LOW DISEASE ACTIVITY MONITORING

Evaluate that the patient remains within disease goal



Continue to test patient two times a year



Monitor:

Monitor that patient is remaining in treatment goal

